Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 8Thoracic 7Lymphoid 4Genitourinary 4Other hematologic neoplasm 3Gastrointestinal 3Gynecologic 2Dermatologic 2CNS 2NET 1Myeloid 1Endocrine 1Classical hematology 1

Conditions

Recurrence 1Neuroendocrine Tumors 1

Interventions

Everolimus 18lanreotide 7Octreotide 7pembrolizumab 6Sunitinib 6Magnetic Resonance Spectroscopy 5lutetium Lu 177 dotatate 4gallium Ga 68 dotatate 4cabozantinib 4Nivolumab 4Carboplatin 4telotristat ethyl 3pasireotide 3lenvatinib 3arginyllysine 3Temozolomide 3Specimen Handling 3Etoposide 3Erlotinib Hydrochloride 3Bevacizumab 3surufatinib 2pazopanib 2amino-acid, glucose, and electrolyte solution 2X-Rays 2Sorafenib 2Phantoms, Imaging 2Paclitaxel 2Oxaliplatin 2Ipilimumab 2Doxorubicin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × entinostat × NET × Clear all
NCT03211988 2026-03-02

Entinostat Neuroendocrine (NE) Tumor

Columbia University

Phase 2 Terminated
5 enrolled 9 charts
EndocrineNET

Recurrence, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡